If you are short-term, leave! A gentleman does not stand under a dangerous wall!
If you are in the middle line, or if you are forced to be in the middle line, continue to hold it! After all, 000518’s increase this year is not big! You may feel more confident with the following information!
Individual stocks fell more than they rose. If it were not for the sharp rise of Changdian and Bank of China, the Shanghai Stock Exchange Index would have completely closed in the green. The Shenzhen Component Index fell 53 points, apparently rationally telling investors that the market risks of individual stocks have emerged. At the current stage, it is no longer advisable to chase high prices. Instead, it is a low-priced product in the market, because the low price will become a safe haven for funds. Sihuan Biotech (000518), the current share price is only more than 2 yuan, and it will usher in a long-term adjustment. Break through the market upward.
One of the investment highlights: Biomedicine has huge development potential
Biomedicine is known as the sunrise industry with the most development potential in the 21st century, and Sihuan Biotech is a well-deserved leader in my country's biogene industry. of faucet. As my country's earliest enterprise engaged in research, pilot testing, production and sales of genetically engineered drugs and diagnostic reagents, the company is the leader in my country's biogenetic industry. The recombinant human interleukin-2 injection produced by it is the first in China and the only water injection product in the world. This product is a national first-class biological product and is mainly used for patients with various malignant tumors, tuberculosis, hepatitis, AIDS, etc. The treatment of infectious patients can effectively improve the body's immune function, and the market prospects are extremely promising. The company has exclusive products and new drugs that are widely used in the market, which demonstrates the company's outstanding strength in the field of biopharmaceuticals. In recent years, Sihuan Biotechnology has used raised funds to expand the pharmaceutical industry. While acquiring two pharmaceutical companies, the company has also invested heavily in technical transformation and GMP certification of the acquired companies. At present, the company's production lines for raw materials and intermediates, solid preparations, injections and water injections have all passed the GMP certification of the State Food and Drug Administration, and have formed an annual production capacity of nearly 20 million bottles (bags) of large infusion solutions and 1,000 tons of raw materials. production capacity. Such strong production capacity makes Sihuan Biotech a well-deserved pharmaceutical leader in the industry. In the early stage, the company's board of directors decided to transfer 95% of the company's equity in Kunshan Zhonghuan Real Estate Co., Ltd. to Shanghai Xinwanrong Water Conservancy Engineering Technology Co., Ltd. for 41.89 million yuan on July 14, 2005. Information shows that Sihuan Biotech's total investment in Kunshan Zhonghuan is 21.89 million yuan. This time, Xinwanrong received the company's initial investment for 41.89 million yuan, and Sihuan Biotech is expected to receive an investment income of 20 million yuan. , which constitutes a major benefit to the company's performance. For such a lowest-priced leader whose performance is expected to increase significantly, it deserves special attention!
Investment Highlight No. 2: Century Chaoyang Enterprise has a very bright future
What is particularly noteworthy is that the company’s subsidiary controls China Cell Engineering Co., Ltd., which is one of the national 863 Tenth Five-Year Plan major projects. The unit responsible for the project - "Technical Platform for Large-Scale and Efficient Production of Animal Cell Expression Products" and the "Industrialization of Therapeutic Antibodies" in Beijing and other projects, has a number of new technologies and products with independent intellectual property rights, and has mastered international Advanced large-scale and efficient animal cell culture technology is committed to the industrialization of therapeutic antibodies, gene therapy and viral vector vaccines (such as AIDS vaccines, SARS vaccines) and other products in my country. Xie Zhiliang, the founder of China Cell, is an internationally renowned expert in biogenetic engineering and a Ph.D. from the Massachusetts Institute of Technology in the United States. He has mastered the most advanced cutting-edge technology of large-scale animal cell culture in the world. Therefore, through Sihuan Bio's acquisition of China Cell's equity, the company's biogene industry will enter an unconventional development track, and Sihuan Bio is expected to become the true king of the market. It will undoubtedly attract the attention of funds!
Investment Highlight No. 3: Sincere Commitment of Shareholders to Profit in the Performance Year
Disclosure in the 2006 Third Quarter Report: During the reporting period, the company’s industry and business scope did not change, and the company continued to Textile and pharmaceutical products are the main industries. The company's production situation is stable. During the reporting period, with the efforts of the company's management and all employees, it achieved a turnaround from losses to profits. From January to September 2006, the company achieved main business income of 191.0416 million yuan, an increase of 34.88% compared with the same period last year. In 2006, while actively completing the share-trading reform, the company will work hard on production and operations, maintain the continued recovery of sales revenue and net profit, and achieve full-year profits.
The company's textile product, silk corduroy, was granted an invention patent by the State Intellectual Property Office; the company's textile product, "Yilian Huayingba", passed the provincial scientific and technological achievements appraisal of Jiangsu Province and was listed as a provincial new product. All the company's pharmaceutical workshops: injection workshop, tablet workshop, capsule workshop, API workshop, and liquor workshop have passed the Drug GMP certification of the State Food and Drug Administration. The company's subsidiary Beijing Sihuan Biopharmaceutical Co., Ltd. completed the overall relocation of the factory from the Military Compound of the Academy of Military Medical Sciences in Fengtai District, Beijing to
Beijing Yizhuang High-tech Development Zone, and re-approved the National Food and Drug Administration Drug GMP certification from the Supervision and Administration Bureau. In addition, from the share reform plan disclosed by the company, we can see that the major shareholders have full confidence in the company. The company's largest shareholder, Jiangyin Zhenxin Wool Textile Factory, promised to hold the original S Sihuan non-tradable shares from the date of obtaining the right to be listed and circulated. , shall not be listed for trading or transferred within twenty-four months. After the expiration of the above-mentioned lock-in period, the price for sale through the stock exchange shall not be less than 6 yuan. The company's current share price is only 2.5 yuan. There is still room for more than doubling the reduction price.
Investment Highlight No. 4: Absolutely historically low prices and shocking market trends
From the analysis of secondary market trends, the company's fundamentals are in sharp contrast with the company's stock price. One is one of the lowest-priced stocks in the two cities, and the other is the most promising sunrise company in the 21st century. This undoubtedly means a particularly large opportunity for funds that are good at value mining. Especially at this time when new funds are entering the market like crazy, the temptation for such a stock is undoubtedly huge. Since the stock rose like onions above 1 yuan, it has obviously entered a phased shock stage. As the market deepens, the mid-term adjustment of the stock is about to end. The W shape has been completed and is now about to achieve the aggressiveness of breaking through the neckline. The market outlook is relatively broad, so it is recommended to focus on it.